Anavex Life Sciences Corp. (NASDAQ:AVXL) Director Peter D.O. Donhauser purchased 1,165 shares of the firm’s stock in a transaction on Friday, February 19th. The stock was bought at an average price of $12.67 per share, with a total value of $14,760.55. Following the acquisition, the director now owns 1,000 shares in the company, valued at $12,670. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of AVXL traded down $0.77 during trading hours on Tuesday, reaching $12.12. 65,775 shares of the company’s stock traded hands, compared to its average volume of 5,841,588. The firm has a market capitalization of $842.19 million, a price-to-earnings ratio of -25.67 and a beta of 0.70. Anavex Life Sciences Corp. has a twelve month low of $2.20 and a twelve month high of $28.70. The business’s fifty day simple moving average is $8.61 and its two-hundred day simple moving average is $5.78.
Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Wednesday, February 10th. The biotechnology company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.01). On average, research analysts forecast that Anavex Life Sciences Corp. will post -0.46 earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the stock. Opus Capital Group LLC acquired a new stake in Anavex Life Sciences during the 3rd quarter worth about $46,000. Bank of America Corp DE raised its stake in shares of Anavex Life Sciences by 863.0% in the 2nd quarter. Bank of America Corp DE now owns 23,392 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 20,963 shares in the last quarter. GSA Capital Partners LLP raised its stake in shares of Anavex Life Sciences by 68.5% in the 4th quarter. GSA Capital Partners LLP now owns 49,678 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 20,194 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Anavex Life Sciences by 460.0% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 12,364 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 10,156 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new position in shares of Anavex Life Sciences in the 4th quarter valued at approximately $62,000. Institutional investors and hedge funds own 18.92% of the company’s stock.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex.
See Also: Why do corrections happen?
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.